UnknownNot Applicable

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)

Spain1,600 participantsStarted 2019-07-29

Plain-language summary

MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective, uncontrolled study of anticoagulated patients with any direct oral anticoagulant (DOAC) with atrial fibrillation or venous thromboembolism to determine the incidence of serious complications (thromboembolic or hemorrhagic) in real life

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: · Patients older than 18 years. * With atrial fibrillation or recurrent venous thrombosis. * In chronic treatment with any DOAC type drug. * Patients who sign the informed consent Exclusion Criteria: * Patients who do not guarantee collaboration. * Patients with advanced cognitive impairment and not supervised. * Patients with alcoholism. * Patients with psychiatric disorder and not supervised

What they're measuring

Thromboembolic events

Timeframe: 3 years

Major haemorrhagic events

Timeframe: 3 years

Trial details

NCT IDNCT04042155

SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08

Contact for this trial

Juan C Souto, MD, PhD

34-654633993 jsouto@santpau.cat

View on ClinicalTrials.gov More Atrial Fibrillation trials